We are live on
!
Find out more
ICM
Invenomic Capital Management Portfolio holdings
AUM
$2.18B
1-Year Est. Return
0.03%
This Fund
S&P 500
This Quarter
Est. Return
+14.24%
1 Year Est. Return
+0.03%
3 Year Est. Return
-6.37%
5 Year Est. Return
-25.27%
10 Year Est. Return
–
AUM
$2.19B
AUM Growth
-$189M
(-7.9%)
Cap. Flow
-$471M
Cap. Flow
% of AUM
-21.5%
Top 10 Holdings %
Top 10 Hldgs %
25.76%
Holding
204
New
59
Increased
25
Reduced
88
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SolarEdge
SEDG
|
+$41.5M |
| 2 |
Illumina
ILMN
|
+$40.9M |
| 3 |
QuidelOrtho
QDEL
|
+$34.1M |
| 4 |
CIVI
Civitas Resources
CIVI
|
+$18.5M |
| 5 |
FMC
FMC
|
+$17.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$245M |
| 2 |
Apple
AAPL
|
+$85.6M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$56.2M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$40.7M |
| 5 |
Corpay
CPAY
|
+$40.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.91% |
| 2 | Consumer Discretionary | 12.94% |
| 3 | Healthcare | 12.41% |
| 4 | Communication Services | 8.9% |
| 5 | Industrials | 7.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
National Vision
EYE
$1.8B
| $5.87M | 0.27% |
+280,571
| New | +$4.98M |
|
102
Ziff Davis
ZD
$2B
| $5.84M | 0.27% |
86,851
+70,800
| +441% | +$4.49M |
|
103
PRA Group
PRAA
$723M
| $5.77M | 0.26% |
220,228
-35,168
| -14% | -$658K |
|
104
Laureate Education
LAUR
$5.13B
| $5.56M | 0.25% |
405,899
-355,864
| -47% | -$4.88M |
|
105
Sonoco
SON
$5.72B
| $5.46M | 0.25% |
97,813
+32,460
| +50% | +$1.76M |
|
106
UNIFI
UFI
$129M
| $5.42M | 0.25% |
813,753
-73,408
| -8% | -$479K |
|
107
Yext
YEXT
$577M
| $5.3M | 0.24% |
900,362
+530,044
| +143% | +$3.26M |
|
108
ManpowerGroup
MAN
$2.63B
| $5.13M | 0.23% |
+64,500
| New | +$4.79M |
|
109
Avista
AVA
$3.2B
| $4.96M | 0.23% |
+138,789
| New | +$4.7M |
|
110
Baxter International
BAX
$14.4B
| $4.95M | 0.23% |
128,001
-406,535
| -76% | -$14.4M |
|
111
Anika Therapeutics
ANIK
$277M
| $4.77M | 0.22% |
210,332
+116,679
| +125% | +$2.41M |
|
112
Silvercrest Asset Management
SAMG
$77.6M
| $4.51M | 0.21% |
265,540
+50,389
| +23% | +$832K |
|
113
Belden
BDC
$5.28B
| $4.44M | 0.2% |
+57,537
| New | +$4.28M |
|
114
LiveRamp
RAMP
$2.3B
| $4.42M | 0.2% |
116,628
-303,791
| -72% | -$9.76M |
|
115
NETGEAR
NTGR
$619M
| $4.25M | 0.19% |
291,690
-165,687
| -36% | -$2.14M |
|
116
Healthcare Services Group
HCSG
$1.5B
| $4.22M | 0.19% |
+406,588
| New | +$4.06M |
|
|
VMEO
117
DELISTED
Vimeo
VMEO
| $4.2M | 0.19% |
1,071,372
-674,196
| -39% | -$2.41M |
|
118
SandRidge Energy
SD
$531M
| $4.15M | 0.19% |
303,691
-1,272
| -0.4% | -$18.8K |
|
119
Omnicell
OMCL
$1.7B
| $3.94M | 0.18% |
+104,603
| New | +$3.85M |
|
120
Castle Biosciences
CSTL
$988M
| $3.71M | 0.17% |
171,812
-114,145
| -40% | -$2.01M |
|
121
Stride
LRN
$3.33B
| $3.49M | 0.16% |
58,701
-296,489
| -83% | -$16.2M |
|
122
Warby Parker
WRBY
$3.26B
| $3.43M | 0.16% |
+243,395
| New | +$3.03M |
|
123
Whirlpool
WHR
$2.75B
| $3.36M | 0.15% |
+27,555
| New | +$3.21M |
|
124
GoodRx Holdings
GDRX
$1.25B
| $3.31M | 0.15% |
494,207
-811,989
| -62% | -$4.57M |
|
125
ZipRecruiter
ZIP
$414M
| $3.26M | 0.15% |
+234,318
| New | +$2.9M |
|
Similar funds
SIG
CAG
ORCP
ET
GC
MIAS
TAL
IIP
Invenomic Capital Management's Q4 2023 Portfolio in Review
As of Q4 2023, Invenomic Capital Management held 204 positions worth $2.19B, down 7.9% from $2.38B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Invenomic Capital Management withdrew a net $471M in Q4 2023, closing 32 positions and reducing 88 holdings. Its most notable exit was State Street SPDR S&P 500 ETF Trust, an estimated $245M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, down from 23% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Invenomic Capital Management opened a new position in SolarEdge worth $42.6M.
- Invenomic Capital Management's largest Q4 2023 buy was SolarEdge: 455,600 shares worth $42.6M.
- Invenomic Capital Management added most to IPG Photonics in Q4 2023, an estimated $11.6M increase.
- Invenomic Capital Management's biggest Q4 2023 reduction was Corpay, cutting an estimated $40.2M.
- Invenomic Capital Management fully exited State Street SPDR S&P 500 ETF Trust in Q4 2023, selling an estimated $245M.
- Invenomic Capital Management's ten largest holdings make up 26% of its $2.19B portfolio in Q4 2023.
- Invenomic Capital Management opened 59 new positions and closed 32 in Q4 2023.
- Invenomic Capital Management's portfolio value fell 7.9% quarter-over-quarter to $2.19B.
Based on Invenomic Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.